Research Synthesis: Rapamycin Biomarker Rates

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Remove or fix the recurring 'Animal/preclinical context (…):' preface tags that are incorrectly attached to paragraphs about direct human RCTs (e.g., the Results subsections on Contextual Adjacent Evidence and Dosing and Pharmacokinetics).
2. Reconcile Mandrioli 2023 direction coding: either keep 'positive on secondary inflammatory biomarkers' or 'null on primary Treg endpoint,' but use consistent wording in Abstract, Findings Map, Cross-Domain Synthesis, and Results.
3. Provide the exact bundle token (quote or DOI/PMID page span) supporting any exact p-value or effect estimate cited in the Findings Map or Evidence Snapshot, or recast as 'reported in source, not verifiable in bundle excerpt.'
4. Resolve the Stanfield 2024 internal contradiction: the Results claim that no numerics are available, while the Evidence Snapshot cites a representative statistic for Stanfield 2024 — pick one framing and align the other section.
5. Clarify or correct the Stanfield 2026 'P < 0.001' statistic cited in the Evidence Snapshot if it is not present in the bundle excerpt.
6. Delete the boilerplate/word-floor/recommendation-boundary paragraphs that do not advance evidence synthesis (Abstract closing paragraph; scattered 'public word floor' lines).
7. Tighten the Methods funnel explanation: clarify that 'No records were excluded at the gates' refers to post-admission screening rather than the entire pipeline, since the funnel lists non-admitted buckets.
8. Justify inclusion of Wick 2025 (temsirolimus, not rapamycin) under the 'rapamycin biomarker rates' topic or flag it as a structural corpus limitation.
9. Make Stanfield 2024 and Stanfield 2026 evidence-pending if no numerics can be cited, and remove unverified effect-direction inferences.

Major issues

• The Abstract and several sections contain an 'Animal/preclinical context' preface tag that is textually attached to in-text claims but whose referenced source (e.g., Stanfield 2024, Roark 2025, Shaverdian 2026) does not match the claim being qualified — this looks like a templating/insertion error that injects misleading provenance labels into multiple paragraphs and must be fixed.
• The Stanfield 2024 muscle-function Results section claims 'no p-values, effect sizes, or sample sizes are reported in the available source excerpt,' yet the Evidence Snapshot reports a representative statistic for Stanfield 2024 and the bundle excerpt includes sample size (n=40, age range, etc.); this internal contradiction is material.
• The Mandrioli 2023 effect direction is coded 'positive' in the bundle and Findings Map (positive on inflammation: IL-18, classical monocytes), but several prose passages frame the Mandrioli result as null on the primary endpoint and the manuscript inconsistently labels it across sections (positive vs unclear/null), creating claim-direction ambiguity.
• The Stanfield 2026 representative statistic 'P < 0.001' cited in the Evidence Snapshot does not appear in the bundle excerpt and contradicts the source's 'primary outcome' reporting; the bundle quotes only design details without that p-value, and this statistic cannot be verified against the bundle.
• Exact effect-direction and magnitude claims for Stanfield 2024 and Stanfield 2026 rest on numerics that are not traceable to the bundle excerpts provided (the calibration rule for reference-only bundles requires exact token or DOI/PMID support), so they should either be cited with the exact bundle token they came from or restated as evidence-pending.
• Several sections appear to be template/boilerplate padding ('In this section, the paragraph is tied to the local interpretive task…', 'The public word floor is preserved…') that does not advance evidence synthesis and adds no source-traceable content; these must be trimmed or rewritten as substantive synthesis.
• The Methods section contains an internal inconsistency: it states 'No records were excluded at the gates instrumented for this run' but lists 'No extractable claims (n=43)' and several other non-admitted buckets in the funnel, which is contradictory and needs clarification.

Minor issues

• The phrase 'Evidence-honesty note' and the boilerplate 'public word floor' / 'recommendation-boundary safeguard' language in the Abstract and Background reads as filler that should be removed for a publishable artefact.
• Some figures in the Findings Map and Results tables (e.g., 'significant source statistic in 8/9 sources') are not defined in the Methods and should be operationalized.
• The Conclusion repeats tier and directness counts from the Results rather than synthesizing — consider tightening.
• Risk-of-bias field is null for most sources; the manuscript notes this, but a clearer statement of which sources did receive RoB ratings would improve auditability.
• The 'Search Summary' section is a verbatim duplicate of the Methods 'Search strategy' block; one should be removed.
• Wick 2025 is a glioblastoma umbrella trial that used temsirolimus (a rapalog) rather than rapamycin itself — the consistent inclusion under 'rapamycin biomarker rates' should be justified or flagged as a structural limitation.

Reviewer note

This is a long-form, scoping-style synthesis of 19 sources on rapamycin biomarker rates, organized around five outcome classes with an explicit directness/tier framework and an Evidence Snapshot that resembles a quantitative index. The structural ambition and depth (Findings Map, Cross-Domain Synthesis, Boundary-Condition Matrix, Gap Priority, Endpoint-Sensitivity Framework) are appropriate for a gatekeeper-tier research-synthesis artefact, and the manuscript is generally honest about its limits. However, several material defects block acceptance. First, a templating artifact ('Animal/preclinical context (…)') appears at the head of multiple prose paragraphs and is mis-attached to claims that are about direct human RCTs (Mandrioli 2023, Ruan 2025, Stanfield 2024). This is a textual-integrity issue, even if not a malicious one, and it must be cleaned up before publishing. Second, internal contradictions around Mandrioli 2023's direction (positive on IL-18/monocytes vs null on the primary Treg endpoint) and Stanfield 2024 (Results says no numerics, Evidence Snapshot cites a statistic) create ambiguity about what the corpus actually supports. Third, several exact statistics (Stanfield 2026 P < 0.001; some Stanfield 2024 numerics) cannot be verified against the provided bundle excerpts. Under the calibration rule for reference-only bundles, these should either be cited with a verifiable token or downgraded to evidence-pending language. The synthesis quality is adequate: there is real integration across domains (surrogate-vs-hard-outcome tension, indication-specificity boundary, directness gradient across outcome classes), and the Cross-Domain Synthesis is the strongest part of the paper. Limitations and gaps are present but generic in places, and the recurring boilerplate ('public word floor', 'recommendation-boundary safeguard') reads as filler rather than synthesis. The source bundle is otherwise coherent, recent, and reasonably matched to the manuscript's thesis. Recommendation: revise. The paper is mostly correct and fixable with bounded edits — the framework, the inclusion logic, and the bounded conclusion are sound — but the integrity defects above must be repaired before acceptance.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v12-grounded-integrity